trans

Translational Software announces strategic partnership with AKESOgen

 
Translational Software announces strategic partnership with AKESOgen
 

Mercer Island, WA & Norcross, GA – November 14, 2014 – Translational Software, Inc., a leader in integrating genetic information into mainstream clinical care, has announced a strategic partnership with AKESOgen, Inc., an integrated genomics and pharmacogenetics company, to provide translational interpretation and analysis of genotyping.

Based near Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors.

The collaboration provides AKESOgen with the capabilities of Translational Software’s powerful Genomic Insight Solution (GIS). GIS transforms complex molecular data into information clinicians can easily interpret and understand with an advanced, cloud-based solution. It harnesses the company’s proprietary knowledge base-developed from only the most current and relevant clinical evidence-coupled with advanced laboratory molecular data.

“Translational Software provides an important dimension in assisting clinicians with easy to understand analysis and guidance,” said Bob Boisjoli, CEO of AKESOgen. “We share a common goal of enhancing diagnostic confidence, satisfaction and efficiency among healthcare professionals leading to better outcomes for patients.”

“AKESOgen is a leader in molecular genetic technologies, and is particularly known for its outstanding delivery of service,” said Translational Software CEO Don Rule. “We are excited provide another component to AKESOgen’s suite of services.”

About Translational Software, Inc.

Translational Software is at the forefront of integrating genetic information into mainstream clinical care. The company works with molecular testing labs–serving over 5,000 practitioners–by providing market-focused services with end-to-end solutions to support physicians adopting personalized medicine. Its Genomic Insight Solution (GIS) generates relevant reports for referring clinicians with easy-to-understand recommendations and guidance on therapeutic options for their medication management. The reports include information targeted to clinical specialties, and GIS can be integrated with existing Laboratory Information Systems (LIS) to significantly reduce costs and turnaround time. For more information, visit www.translationalsoftware.com

 

About AKESOgen, Inc.

AKESOgen is an integrated genomics and genetics company providing high-throughput, biomarker profiling, cytogenetics and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA/GLP standards. The company’s main focus is oncology and personalized medicine. Based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, and government sectors for research use, diagnostic clinical testing and clinical trials services. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

 

–ENDS–
Media Contacts
Rick Shigaki, Vice President of Sales and Marketing, Translational Software
Office: (206) 777-4396
Email: rick.shigaki@translationalsoftware.com

Barry Bartlett, The Bartlett Group
Mobile: (206) 335-4694
Email: barry@bartlettgrouppr.com

Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.
Office: (770) 542-0890
Email: mbouzyk@akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail